Telomir Pharmaceuticals (TELO) Projected to Post Quarterly Earnings on Monday

Telomir Pharmaceuticals (NASDAQ:TELO) is anticipated to issue its quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Telomir Pharmaceuticals Stock Performance

Shares of Telomir Pharmaceuticals stock opened at $2.49 on Friday. The company has a market capitalization of $74.11 million, a P/E ratio of -4.29 and a beta of 0.17. The company has a fifty day moving average of $3.26 and a 200 day moving average of $4.07. Telomir Pharmaceuticals has a fifty-two week low of $2.35 and a fifty-two week high of $8.40.

Institutional Trading of Telomir Pharmaceuticals

An institutional investor recently raised its position in Telomir Pharmaceuticals stock. Bank of America Corp DE increased its holdings in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 283.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,713 shares of the company’s stock after buying an additional 10,880 shares during the quarter. Bank of America Corp DE’s holdings in Telomir Pharmaceuticals were worth $61,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Wall Street Analyst Weigh In

TELO has been the subject of several research reports. Rodman & Renshaw initiated coverage on Telomir Pharmaceuticals in a report on Friday, February 21st. They issued a “buy” rating and a $15.00 target price for the company. RODMAN&RENSHAW raised shares of Telomir Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, February 20th.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.